Literature DB >> 21975059

Early diagnosis and resection of an asymptomatic leiomyosarcoma of the inferior vena cava prior to caval obstruction.

Fabio Ramponi1, James G Kench, Dominic V Simring, Michael Crawford, Edward Abadir, John P Harris.   

Abstract

Leiomyosarcoma of the inferior vena cava is a rare and aggressive tumor, characterized by a slow growth and usually late diagnosis. The mainstay of therapy is surgical resection with limited role for chemotherapy or radiotherapy; resection modalities and the need for caval reconstruction are still matters of debate. In this case report, we describe an asymptomatic intraluminal leiomyosarcoma of the inferior vena cava diagnosed incidentally prior to caval occlusion during a routine ultrasound examination of the upper abdomen.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21975059     DOI: 10.1016/j.jvs.2011.06.112

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

1.  Leiomyosarcoma of the inferior vena cava level II involvement: curative resection and reconstruction of renal veins.

Authors:  Quan Wang; Jing Jiang; Chao Wang; Guodong Lian; Mei-Shan Jin; Xueyuan Cao
Journal:  World J Surg Oncol       Date:  2012-06-28       Impact factor: 2.754

2.  Primary Leiomyosarcoma in the Inferior Vena Cava Extended to the Right Atrium: A Case Report and Review of the Literature.

Authors:  Shuichi Fujita; Hideaki Takahashi; Yumiko Kanzaki; Tomohiro Fujisaka; Yoshihiro Takeda; Hideki Ozawa; Hiroko Kuwabara; Takahiro Katsumata; Nobukazu Ishizaka
Journal:  Case Rep Oncol       Date:  2016-10-12

3.  Leiomyosarcoma of the inferior vena cava: Survival rate following radical resection.

Authors:  Frederico José Ribeiro Teixeira; Sergio Dias do Couto Netto; André Luis de Freitas Perina; Fabio C M Torricelli; Luciana Ragazzo Teixeira; Antonio Eduardo Zerati; Fabio de Oliveira Ferreira; Eduardo Hiroshi Akaishi; William Carlos Nahas; Edivaldo Massazo Utiyama
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.